COMPARATIVE VERDICT
Selank vs Semax: A Research Comparison
Two peptides, one Russian institute, two divergent published profiles. Anxiolysis vs cognition. Tuftsin vs ACTH. Read the actual differences.
Selank vs Semax: which has stronger evidence?
The Selank vs Semax question gets asked as if it had a single answer. It does not. Both peptides were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and registered in Russian pharmacopoeia. Both inhibit enkephalin-degrading enzymes [2]. Both are absent from the FDA, EMA, MHRA, and TGA approval registers.
The divergence is in primary indication and trial endpoint design. Selank's principal published controlled human trial is the 62-patient Zozulia (2008) generalized-anxiety study, which framed Selank as an anxiolytic comparable to medazepam with additional antiasthenic effects [1]. Semax's published profile clusters around cognitive and neurotrophic endpoints — stroke recovery, attention, executive function — derived from its ACTH(4-10) lineage.
Neither molecule has the kind of large, multi-center, Western-replicated trial portfolio that would settle the comparison. The honest answer to which has stronger evidence depends on the endpoint you care about. For anxiety, Selank has the single largest published controlled trial. For cognition, Semax's trial endpoints are more directly cognitive.
STRUCTURAL AND PHARMACOLOGICAL DIFFERENCES
Structural and pharmacological differences
The structural starting point is different. Selank is a heptapeptide: Thr-Lys-Pro-Arg-Pro-Gly-Pro — tuftsin (Thr-Lys-Pro-Arg, from immunoglobulin G) extended with Pro-Gly-Pro to slow plasma carboxypeptidases. Semax is a heptapeptide derived from ACTH(4-10) — Met-Glu-His-Phe-Pro-Gly-Pro — also stabilized with the same Pro-Gly-Pro C-terminal extension.
The parent-molecule difference predicts the pharmacology difference. Tuftsin is immunomodulatory and ties into the endogenous opioid system; Selank's profile reflects that lineage with enkephalinase inhibition [2], Th1/Th2 cytokine effects [10], and naloxone-reversible behavioral actions [21]. ACTH(4-10) is a melanocortin-system fragment with documented cognitive and neurotrophic effects in its own right; Semax's published profile reflects that lineage.
Both peptides modulate BDNF in hippocampus and prefrontal cortex in rodent work, and both inhibit enkephalin-degrading enzymes in serum [2][4]. The overlap is real. The primary published indication is different.
Cognitive endpoints across studies
Is Semax or Selank better for brain fog? The cognitive endpoint literature differs in framing more than in conclusion. Semax's cognitive trial endpoints are primary; Selank's cognitive findings emerge as secondary readouts in studies primarily framed around anxiolytic, neurotrophic, or protective effects.
For Selank, the cognitive record is real but secondary: BDNF up-regulation in hippocampus and prefrontal cortex [4][5], compensatory memory effects after DSP-4 noradrenergic lesion [15], memory protection under pharmacological protein-synthesis blockade [16], and restoration of integrative brain activity in rats following antenatal hypoxia [18].
Neither molecule has the Western controlled cognitive-trial portfolio that would let a head-to-head head-fog comparison resolve at confidence.
COMBINATION PROTOCOLS IN THE LITERATURE
Combination protocols in the literature
Should Semax and Selank be taken together? Anecdotal stacking is common in user reports; published controlled co-administration data is limited to preclinical and observational work. We do not document a human controlled-trial record of combined Semax-Selank dosing in the English-PubMed-indexed literature.
What the literature does show: Selank potentiates diazepam's anxiolytic effect in the rat unpredictable chronic mild stress model [7], consistent with functional coupling at benzodiazepine-sensitive GABAA sites. Combination work with Semax in particular has not generated a Western-trial record.